Engineering solutions for complex genetic diseases
GrittGene Therapeutics is building a scalable, AI-driven platform to decode and treat complex genetic and muscle-related diseases
Decoding and treating genetically complex diseases
GrittGene Therapeutics is building a scalable, AI-powered platform to decode and treat genetically complex, mechanistically heterogeneous diseases.
Our platform integrates transcriptomics, proteomics, and epigenomics with artificial intelligence to uncover disease mechanisms and identify high-confidence therapeutic targets.
Starting with Myotonic Dystrophy Type 2
We begin with Myotonic Dystrophy Type 2 (DM2), a high-unmet-need, multisystem disorder, as our clinical and scientific entry point into a broader landscape of underserved genetic diseases.
Cell Therapy
Gene Therapy
Biologics
Diagnostics
A diversified, multi-modality pipeline designed to create multiple paths to clinical and commercial success.
Built to scale beyond a single disease
While DM2 is our entry point, our technology is inherently scalable across complex genetic disorders. Our muscle regeneration cell therapy programs alone extend into large adjacent markets, including neuromuscular diseases and age-related muscle loss.
A partnership-driven development model
Built as a capital-efficient, partnership-first model, we leverage external innovation and expertise to move faster, reduce fixed costs, and maximize capital efficiency.
We are not building a single asset—we are building a repeatable engine for generating and scaling high-impact therapies across multiple high-need indications.
